• In addition to G-CSF, the use of ATRA in the context of acute promyelocytic leukemia has shown the propagation of aberrant neutrophils as seen in drug-induced Sweet syndrome. (medscape.com)
  • Acute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML). (medscape.com)
  • Those studies showed that acute leukemia occurred in .07 percent to .25 percent of MS patients taking mitoxantrone. (scienceblog.com)
  • The potential risk of leukemia should be carefully considered against the potential benefits of mitoxantrone treatment on every single patient. (scienceblog.com)
  • It is vital that all MS patients treated with mitoxantrone undergo prolonged and careful hematological follow-up to check for acute leukemia," Martinelli said. (scienceblog.com)
  • Because mitoxantrone (MTX) is a strong BCRP substrate and is often used in the treatment of leukemia, we investigated the effect of 24 h proadifen pre-treatment on the cytotoxicity of MTX in leukemic cell lines that are sensitive to MTX (HL-60) and MTX-resistant ABCG2-overexpressing subclone (cBCRP). (spandidos-publications.com)
  • Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing more than a quarter of all pediatric cancers. (medscape.com)
  • The image below depicts bone marrow aspirate from a child with T-cell acute lymphoblastic leukemia. (medscape.com)
  • Also, see the Childhood Acute Lymphoblastic Leukemia: Diagnosis, Management, and Complications slideshow to help recognize and treat this disease and its associated complications. (medscape.com)
  • Children with acute lymphoblastic leukemia (ALL) often present with signs and symptoms that reflect bone marrow infiltration and/or extramedullary disease. (medscape.com)
  • See Acute Lymphoblastic Leukemia Staging for more complete information. (medscape.com)
  • Mitoxantrone is a member of the antibiotics/antineoplastics drug class and is commonly used for Acute Nonlymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Sclerosis, and others. (drugs.com)
  • One of the drawbacks of mitoxantrone-and it has several-is that once a cumulative dose of 140 mg/m 2 has been reached, risk of leukemia and cardiotoxicity in the form of congestive heart failure emerges. (psychiatrictimes.com)
  • Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age. (stembook.org)
  • Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. (stembook.org)
  • Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. (stembook.org)
  • Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. (stembook.org)
  • Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. (stembook.org)
  • A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. (stembook.org)
  • Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. (stembook.org)
  • Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. (stembook.org)
  • Although outcomes of children and adolescents with newly diagnosed acute myeloid leukemia (AML) have improved significantly over the past two decades, more than one-third of patients continue to relapse and experience suboptimal long-term outcomes. (haematologica.org)
  • Antineoplastic agents are used for induction, consolidation, and maintenance therapy and central nervous system (CNS) prophylaxis in patients with acute lymphoblastic leukemia (ALL). (medscape.com)
  • Corticosteroids may be used during induction, consolidation, and/or maintenance therapy for acute lymphoblastic leukemia (ALL). (medscape.com)
  • Acute Myeloid Leukemia. (bioprofarma-bago.com.ar)
  • Acute Promyelocytic Leukemia. (bioprofarma-bago.com.ar)
  • Acute Monocytic Leukemia. (bioprofarma-bago.com.ar)
  • Acute Erythroid Leukemia. (bioprofarma-bago.com.ar)
  • Hermanson , David L. et al "Overexpression of Mcl-1 Confers Multidrug Resistance, Whereas Topoisomerase II β Downregulation Introduces Mitoxantrone-Specific Drug Resistance in Acute Myeloid Leukemia. (aspetjournals.org)
  • This has also caused more attention to be focused on the evolution of lower- and higher-risk MDS into more aggressive forms of either MDS or acute myeloid leukemia (AML), and has necessitated a clearer description of how these drugs are being used across the country. (jnccn.org)
  • Despite the high cure rates in childhood acute lymphoblastic leukemia (ALL) relapsed ALL remains a significant clinical problem. (bioskinrevive.com)
  • acute myeloid leukemia cell line U937 and acute promyelocytic leukemia cell line NB4 cells were incubated in human BMSC cell line HS-5 derived CM treated with 10 nM of mitoxantrone (Mito) for 6 days and then maintained in drug-free medium Homoharringtonine for 3 months. (bioskinrevive.com)
  • Despite aggressive chemotherapy including mitoxantrone and etoposide, relapse occurs for almost half of children with acute myeloid leukemia (AML). (oncotarget.com)
  • Implications of FLT3 mutations in the therapy of acute myeloid leukemia. (uchicago.edu)
  • Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. (uchicago.edu)
  • The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. (ashpublications.org)
  • In Section III, Dr. Martin Tallman describes the evaluation and management of patients with acute promyelocytic leukemia, a notable example of therapeutic progress in a molecularly defined entity of leukemia. (ashpublications.org)
  • The term acute myeloid leukemia (AML) collectively refers to a mixture of distinct diseases that differ with regard to their pathogenetic evolution, genetic abnormalities, clinical features, response to therapy, and prognosis. (ashpublications.org)
  • Differential in Vitro Drug Resistance Profile Between First and Second Relapsed Acute Lymphoblastic Leukemia and Acute Myeloblastic Leukemia in Children. (krakow.pl)
  • Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. (krakow.pl)
  • B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. (biomedcentral.com)
  • Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). (biomedcentral.com)
  • ONUREG ® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. (onuregpro.com)
  • To explore correlations between CD7, CD34, CD56 and HLA-DR expressions and its prognosis among patients with acute myeloid leukemia. (biomedres.info)
  • 225 patients with Acute Myeloid Leukemia (AML) with initial treatment and complete data in our hospital from Jan 2013 to Dec 2016 were selected as study objects. (biomedres.info)
  • Complete remission rate of CD7, CD34, CD56 and HLA-DR antigen expression positive among patients with Acute Myeloid Leukemia (AML) is low, mean survival is short and prognosis is poor. (biomedres.info)
  • Acute myeloid leukemia (AML), Immunophenotype, Prognosis. (biomedres.info)
  • However, the acute myelogenous leukemia is mainly a recognizable acute leukemia subtype, secondary to chemotherapy, radiotherapy or acute leukemia with definite environmental or occupational exposure history. (biomedres.info)
  • Therefore, this study selects 225 patients with Acute Myeloid Leukemia (AML) in our hospital from Jan 2013 to Dec 2016 as study objects to explore CD7, CD34, CD56 and HLA-DR expression antigen and its relations with clinical effects and prognosis. (biomedres.info)
  • Acute myelogenous leukemia (AML) is a blood cancer that affects white blood cells, red blood cells, and/or platelets. (oncolink.org)
  • AML may also be called acute myelocytic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. (oncolink.org)
  • Acute myeloid leukemia (AML) and related neoplasms. (oncolink.org)
  • In acute myeloid leukemia (AML), malignant transformation and uncontrolled proliferation of an abnormally differentiated, long-lived myeloid progenitor cell results in high circulating numbers of immature blood cells and replacement of normal marrow by malignant cells. (msdmanuals.com)
  • The American Cancer Society estimates that in the United States in 2023 there will be about 20,000 new cases of acute myeloid leukemia (AML) and about 11,300 deaths , almost all in adults. (msdmanuals.com)
  • it is the most common acute leukemia in adults, with a median age of onset of 68 years. (msdmanuals.com)
  • acute myeloid leukemia is caused by a series of acquired genetic aberrations. (msdmanuals.com)
  • Acute myeloid leukemia has a number of subtypes and precursor neoplasms that are distinguished from each other by morphology, immunophenotype, cytochemistry, and genetic abnormalities (see also The 2016 World Health Organization [WHO] Classification of myeloid neoplasms ) all of which have important implications for prognosis and treatment. (msdmanuals.com)
  • Acute promyelocytic leukemia (APL) is a subtype of AML with recurrent genetic abnormalities. (msdmanuals.com)
  • Acute myeloid leukemia (AML) is a disease with a significant amount of cytogenetic heterogeneity including mixed-lineage leukemia (MLL) gene rearrangements. (biomedcentral.com)
  • A 10-year-old Caucasian girl presented with easy bruising and was found to have acute myeloid leukemia. (biomedcentral.com)
  • When considering treatment of acute myeloid leukemia (AML), response to induction therapy and specific cytogenetic abnormalities such as t(8;21), inv(16), NPM, CEBPα, FLT3/ITD+, monosomy 7, monosomy 5, and del5q are the mainstays used to determine risk-directed therapy. (biomedcentral.com)
  • There are a few TOP2A inhibitors currently approved and available on the market, with mitoxantrone (a drug used in the treatment of acute leukemia) the better known. (healthtree.org)
  • The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. (stanfordhealthcare.org)
  • Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study. (krakow.pl)
  • Acute leukemias of ambiguous lineage. (oncolink.org)
  • The addition of mitoxantrone (Novantrone) to interferon beta-1b (IFN beta-1b, Betaseron) therapy for the treatment of patients with aggressive multiple sclerosis (MS) unresponsive to standard therapy may reduce the number of new enhancing lesions as well as life-threatening risks associated with mitoxantrone therapy. (psychiatrictimes.com)
  • Marburg acute multiple sclerosis, also known as Marburg multiple sclerosis or acute fulminant multiple sclerosis, is considered one of the multiple sclerosis borderline diseases, which is a collection of diseases classified by some as MS variants and by others as different diseases. (wikipedia.org)
  • Les formes frontières de sclérose en plaques" [Borderline forms of multiple sclerosis]. (wikipedia.org)
  • Mitoxantrone is an immunosuppressant drug approved by the FDA for treatment of several forms of advancing MS. It is one of only two drugs that has been shown to benefit people with secondary progressive MS who are having attacks. (scienceblog.com)
  • These immunomodulators are now a first-line treatment of relapsing-remitting (RR) and relapsing-progressive (RP) MS. In 2000, mitoxantrone - a cytolytic immunosuppressant - was approved for the treatment of patients with a rapidly progressive disease. (touchneurology.com)
  • After mitoxantrone was added to the initial IFN beta-1b therapy, enhancing lesion frequency was reduced by an average of 90%, enhancing lesion volume decreased by 96%, and relapse rates decreased by 70% at month 7. (psychiatrictimes.com)
  • At these low concentrations, mitoxantrone demonstrated selectivity toward malignant cells over normal pancreatic epithelial cells. (biomedcentral.com)
  • The cost for mitoxantrone intravenous solution (2 mg/mL) is around $186 for a supply of 10 milliliters, depending on the pharmacy you visit. (drugs.com)
  • Each mL of sterile, aqueous solution for intravenous injection contains 2 mg mitoxantrone hydrochloride. (mediresource.com)
  • DNA-PK inhibition alleviated mitoxantrone resistance for AML cells on and off stromal cells. (oncotarget.com)
  • Additionally, low stroma-induced STAT3 activity and strong stroma-induced mitoxantrone resistance were associated with inferior clinical outcome. (oncotarget.com)
  • The study participants all had at least one cycle of mitoxantrone treatment and were observed for at least one year. (scienceblog.com)
  • Moreover, BCRP is very often upregulated in cells undergoing mitoxantrone (MTX) treatment ( 7 ). (spandidos-publications.com)
  • The results of Jeffery's study suggest that a longer duration of treatment with mitoxantrone may result in a greater reduction in disease activity. (psychiatrictimes.com)
  • Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. (mcmaster.ca)
  • The recommended dose and dosing schedule of mitoxantrone varies according to the specific condition being treated, the response to therapy, the other medications or treatments being used and the body size of the person receiving treatment. (mediresource.com)
  • Robert Douglas Sweet first described acute febrile neutrophilic dermatosis in 1964, leading to the eponym Sweet syndrome (SS). (medscape.com)
  • Sweet syndrome (acute febrile neutrophilic dermatosis) is a hypersensitivity reaction that occurs in response to systemic factors, such as hematologic disease, infection, inflammation, vaccination, or drug exposure. (medscape.com)
  • When we added mitoxantrone to the therapeutic regimen of patients who were breaking through with IFN beta-1b, the disease activity measured by MRI in clinical parameters was remarkably diminished,' said Douglas Jeffery, MD, PhD, associate professor in neurology at Wake Forest University School of Medicine in Winston-Salem, North Carolina. (psychiatrictimes.com)
  • Recent evidence shows that Marburg's presents a heterogeneous response to medication, as does standard MS. Historically, acute MS was a fatal disease, with death occurring within a year of onset, often secondary to extensive brainstem demyelination. (wikipedia.org)
  • Mitoxantrone can cause nausea and vomiting, but it is important to keep using this medication even if you feel ill. (mediresource.com)
  • It is usually lethal, but it has been found to be responsive to Mitoxantrone and Alemtuzumab, and it has also been responsive to autologous stem cell transplantation. (wikipedia.org)
  • The combination of IFN beta-1b and mitoxantrone reduces these adverse effects, which are associated with mitoxantrone therapy, while effectively suppressing MS-associated inflammation, explained Jeffery. (psychiatrictimes.com)
  • T2 lesion burden and T1 hypointense lesion burden increased slightly during the baseline phase and decreased after initiation of mitoxantrone therapy. (psychiatrictimes.com)
  • We use mitoxantrone in patients who have had an inadequate response to optimal immunomodulating therapy, whose MS is worsening, or in those who have extremely aggressive disease right from the onset,' said Jeffery. (psychiatrictimes.com)
  • Acute side effects of radiation therapy may be noted and result in colitis and rectal irritation. (livs.org)
  • In particular, mitoxantrone and mithramycin demonstrated significant synergy with TRAIL and led to reduction of cancer cell viability at concentrations lower than 1 μM. (biomedcentral.com)
  • As well as interfering with the genetic material DNA of cancer cells, mitoxantrone can interfere with some of your normal cells. (mediresource.com)
  • When Jeffery and colleagues combined mitoxantrone and IFN beta-1b therapies, symptoms and disease activity substantially declined in patients participating in a pilot trial. (psychiatrictimes.com)